Amrie Grammer, PhD
COO & CSO
Amrie is the Majority Owner and Co-Founder of AMPEL BioSolutions, located in downtown Charlottesville Virginia. Amrie is a Translational Immunologist specializing in human Autoimmune Diseases. She trained at UVA (BS Chemistry, MS Pharmacology) before receiving her PhD in Immunology at UTSW Medical Center at Dallas. Amrie was recruited to the NIH to establish the B Cell Biology Group in the Autoimmunity Branch of NIAMS during the human genome sequencing project. She received multiple NIH awards for her work comparing signaling pathways and genes expressed in patients vs healthy individuals, including the prestigious Director’s Award.
Amrie founded AMPEL in 2013 to bring precision medicine to individual patients, especially those suffering from lupus to whom she has dedicated her career. Over the last six years, she has used her knowledge to design and implement a pipeline to predict disease activity and the “right drug for the right patient at the right time”. In addition, top drugs she identified for repositioning into lupus have had positive clinical trials. Amrie is a member of Sigma Xi and Sigma Delta Epsilon. She serves as a Chair of the UVA Alumni Board of the professional Chemistry Fraternity, Alpha Chi Sigma. In December 2016, Amrie was elected to the Board of Directors of the Virginia Biotechnology Association (VA Bio). She is also a board member of the University of Virginia Fralin Art museum (2011-present).
Peter Lipsky, MD
CEO & Director of Clinical Operations
Peter is a Rheumatologist & Immunologist who specializes in basic & clinical research. He received his medical degree from the New York University School of Medicine, completed residency training at the Strong Memorial Hospital in Rochester, New York and his post-doctoral fellowship in NIAID at the NIH. After going to UT Southwestern Medical Center at Dallas, Peter rapidly advanced to become a professor of Internal Medicine and Microbiology as well as the Director of the Harold C Simmons Arthritis Research Center, Co-Director of the Immunology Graduate Program, and Director of the Rheumatic Disease Division of the Department of Internal Medicine. He entered the new millennium as the Director of the Intramural Research Program & the Autoimmunity Branch of NIAMS at the NIH.
Peter is the co-founder of AMPEL BioSolutions LLC and directs its clinical operations focused on autoimmune and inflammatory diseases. Lupus successes include a Phase IIb trial of Stelara/Usekinumab as well as testing of two different ePRO mobile apps in Phase II trials. Ongoing trials include DIVINE which is assessing the ability of 2-D MRI to replace kidney biopsies for lupus patients. In addition, RIFLE is examining the effectiveness of a tolerization regimen of Pegloticase to reduce intolerance to the drug and prolong the urate lowering effect for gout patients.
Peter has edited several journals including the Journal of Immunology, Nature Reviews Rheumatology and Arthritis Research & Therapy. Peter’s accolades include the Carol Nachman Prize, the American College of Rheumatology Distinguished Investigator Award and the Arthritis Foundation’s prestigious Lee Howley prize.